Search

Displaying results 4151 - 4160 of 10000 in total
  1. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results in … [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate

  2. Drug

    Z-Val-Ala-Asp fluoromethyl ketone

    go.drugbank.com/drugs/DB07744
    Experimental

    It does not require an esterase to hydrolyze the O-methyl ester like the cell-permeable form, Z-Val-Ala-Asp(O-Me) fluoromethyl ketone.

    Categories: Compounds used in a research, industrial, or household settingSynonyms: N-[(Benzyloxy)carbonyl]-L-valyl-N-[(2S)-1-carboxy-4-fluoro-3-oxo-2-butanyl]-L-alaninamide
  3. Drug

    Dexamethasone acetate

    go.drugbank.com/drugs/DB14649
    ApprovedInvestigationalVet approved

    one-fifth and one-third in patients on oxygen therapy and mechanical ventilation, respectively. … [L10701] Recently, dexamethasone has been a drug of interest in the treatment of COVID-19.

    Mixtures: BAYCUTEN® N CREMA, BAYCUTEN® N CREMA
  4. Drug

    Betrixaban

    go.drugbank.com/drugs/DB12364
    Approved

    VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients [A27287].

    Synonyms: N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, N-(5-chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide
  5. Drug

    GI-5005

    go.drugbank.com/drugs/DB05942
    Investigational

    Tarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response.

    Categories: Complex Mixtures
  6. Drug

    Squalamine

    go.drugbank.com/drugs/DB06461
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Zuretinol acetate

    go.drugbank.com/drugs/DB12112
    Investigational

    Zuretinol acetate has been used in trials studying the treatment of Impaired Dark Adaptation, RP (Retinitis Pigmentosa), Retinitis Pigmentosa (RP), and LCA (Leber Congenital Amaurosis).

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Quinidine barbiturate

    go.drugbank.com/drugs/DB01346
    Approved

    A papulopurpuric eruption in a patient (without thrombopenia) can be developed who is taking quinidine phenylethyl barbiturate intermittently and at reintroduction.(PMID: 9739909)

  9. Drug

    Oritavancin

    go.drugbank.com/drugs/DB04911
    ApprovedInvestigational

    [A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. … [L12858] Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections.

  10. Drug

    Zinc dibutyldithiocarbamate

    go.drugbank.com/drugs/DB14194
    Approved

    Zinc dibutyldithiocarbamate is a dermatological sensitizer and allergen. Sensitivity to zinc dibutyldithiocarbamate may be identified with a clinical patch test.